Lumexa Imaging (NASDAQ:LMRI) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Lumexa Imaging (NASDAQ:LMRI) issued its quarterly earnings data on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.19, FiscalAI reports. Lumexa Imaging had a negative return on equity of 2.93% and a negative net margin of 1.96%. The firm had revenue of $271.97 million during the quarter.

Here are the key takeaways from Lumexa Imaging’s conference call:

• Q3 systemwide volume grew 4% year over year, with advanced modalities up 8.1% and reaching a record 38.2% of scans. Consolidated revenue was $272 million, while adjusted EBITDA rose 11% sequentially to $62.6 million and margin improved to 23.0%.
• Free cash flow improved to $20.6 million from negative $1.8 million a year earlier, supported by earnings growth, lower interest payments, and more favorable working-capital and JV distribution timing. Management now expects full-year free cash flow conversion of at least 30% of adjusted EBITDA.
• The company narrowed its 2026 adjusted EBITDA guidance to $236 million–$240 million, maintaining the $238 million midpoint, and raised adjusted EPS guidance to $0.86–$0.90, primarily due to a lower assumed tax rate. Revenue guidance was reiterated at $1.045 billion–$1.097 billion.
• Lumexa said the finalized 2027 site-neutral reimbursement rule expands its addressable market from $33 billion to roughly $77 billion, creating a longer-term opportunity to support health systems’ outpatient imaging strategies. It also announced an expanded Advocate Health joint venture that takes the company into Illinois.
• Management’s preliminary assessment is that 2027 Medicare reimbursement will be modestly below its longstanding assumptions—approximately 1% lower—though it expects the overall impact to be limited because Medicare represents about 20% of revenue and most commercial rate negotiations are complete.

Lumexa Imaging Trading Down 4.7%

Shares of LMRI stock traded down $0.76 during trading hours on Thursday, hitting $15.20. 71,451 shares of the company were exchanged, compared to its average volume of 677,170. The firm has a fifty day moving average of $11.33 and a 200 day moving average of $11.08. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The firm has a market cap of $1.46 billion and a PE ratio of -28.16.

Hedge Funds Weigh In On Lumexa Imaging

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Eagle Investment Management LLC purchased a new position in Lumexa Imaging during the third quarter worth approximately $4,753,000. Royce & Associates LP raised its position in shares of Lumexa Imaging by 25.3% in the 3rd quarter. Royce & Associates LP now owns 988,517 shares of the company’s stock worth $10,132,000 after buying an additional 199,477 shares during the period. State of Wyoming acquired a new position in Lumexa Imaging in the third quarter valued at $132,000. Brooklands Fund Management Ltd acquired a new position in Lumexa Imaging in the third quarter valued at $21,577,000. Finally, State of Alaska Department of Revenue purchased a new stake in Lumexa Imaging during the third quarter valued at about $46,000.

Wall Street Analyst Weigh In

Several research firms have weighed in on LMRI. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. UBS Group reaffirmed a “strong-buy” rating on shares of Lumexa Imaging in a research note on Wednesday. KeyCorp initiated coverage on Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective for the company. Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Finally, Barclays upped their target price on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, August 28th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lumexa Imaging currently has a consensus rating of “Buy” and an average target price of $16.80.

Lumexa Imaging Company Profile

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.